Beijing VJTBio Co., Ltd. recently completed a Series C financing round, raising several hundred million yuan. The funds will be mainly used for product research and development, manufacturing site operation, and marketing efforts. This financing will comprehensively enhance the company's integrated competitiveness and marks a solid step towards global products expansion.
VJTBio is a biopharmaceutical company that integrates the R&D, manufacture, and sales of innovative animal drugs, with a primary focus on the multi-billion global animal drug market. The company adhered to the philosophy of "caring for animals, committed of humanity; respecting life, and making medicine with devotion," advocating green and safe farming. It develops high-quality protein drugs with "zero residue" to meet the demands of large-scale intensive farming operations and provide safe meat, eggs, and milk for the public; while developing antibody drugs to treat pet diseases, bringing joy and comfort to pet owners and enhacing the quality of life.
VJTBio is committed to the research and development of recombinant protein and antibody drugs for veterinary use. Its pipeline includes more than ten innovative drug candidates covering three major areas: livestock reproduction, infectious disease prevention and control, and pet disease. Many drug candidates hold global PCT patents and are global pioneers. For livestock reproduction, the company is developing the world's first long-acting recombinant porcine follicle-stimulating hormone, which is expected to replace pregnant mare serum gonadotropin (PMSG) and widely used in synchronizing the estrus of swine, cattle, and sheep, and eventually achieving intensive and efficient reproduction. For infectious disease prevention and control, the company is developing both cytokines and subunit vaccine for preventing and treating major animal diseases. For pet disease, VJTBio is developing multiple antibodies targeting canine and feline tumors, autoimmune diseases, and pain, filling the market gap of pet medications in China. These products are globally patented and are poised for commercialization in the multi-billion-dollar global pet care market. In 2022, VJTBio received strong supported from three key projects under the national "14th Five-Year" plan.
On the core technology front, VJTBio has the world-leading mammalian cell protein expression technology platforms, animal B cell natural antibody libraries and immune libraries. It has established a pet antibody drug design and screening technology platform that includes antibody discovery, bioactivity evaluation and optimization.
Founded in 2016 VJTBio is headquartered Yongfeng Beilun Industrial Park in Haidian District, Beijing, with over 5,000 square meters of R&D and office space. It’s manufacturing site, located in Taizhou, Zhejiang, is the first GMP-certified production line for animal recombinant protein drugs in China, covering over 20,000 square meters. VJTBio has a highly functional team manages the entire biopharmaceutical process, including R&D, registration, manufacturing and commercial sales.